Where There's A Cure There's Controversy: Raymond Schinazi's Story
It is thought that more than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs Raymond F Schinazi has invented. Most latterly associated with hepatitis C cure sofosbuvir, Schinazi tell Jo Shorthouse why he has no intentions of stopping any time soon.
You may also be interested in...
The world’s political tectonic plates may be shifting, but this has done little to undermine the achievements of the pharma, biotech and allied industries over the past year, and last night we celebrated the best of these at the 12th annual Scrip Awards in London.
Just at the moment when markets are more focused on sovereign debt crises and Wall Street is thinking about squatters on its doorstep and looking forward to Thanksgiving, Gilead Sciences steps up and makes an audacious all cash $11 billion bid for Pharmasset. The planned acquisition, which has the full backing of the Pharmasset board, raises more questions than it answers.
The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.